I
Imperagen
Closed-loop AI and robotics platform for digital enzyme evolution
About Imperagen
Imperagen is a Manchester Institute of Biotechnology techbio spin-out building a closed-loop Digital Enzyme Evolution platform that combines quantum-physics simulation, problem-specific AI models and automated robotics to engineer high-performance enzymes for pharmaceuticals, personal care, sustainable chemicals and industrial biotech. Founded by Dr Andrew Almond with Andrew Currin and Timothy Eyes, and led as CEO by Guy Levy-Yurista (joined with the 2026 round), Imperagen reports multi-hundred-fold enzyme productivity gains across few experimental rounds. After a £3.5 million 2022 seed, in May 2026 Imperagen raised a £5 million seed led by PXN Ventures with IQ Capital and Northern Gritstone returning, bringing total funding to about £8.5 million to scale R&D, wet lab and go-to-market. Sources: Tech.eu 21 May 2026; TechCrunch 20 May 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Manchester, United Kingdom
- Sector
- Biotech & Life Sciences
News
Open roles
Imperagen in the Manchester ecosystem
The Imperagen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
IQ Capital
Northern Gritstone
PXN Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Imperagen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imperagen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

